deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT04364048

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer

Sponsor: AstraZeneca

Conditions Lung Cancer Non-small Cell Carcinoma
Interventions Chemotherapy Consolidation durvalumab Induction Durvalumab Radiation
Updated 14 times since 2020 Last updated: Dec 18, 2024 Started: Jun 18, 2020 Primary completion: Jun 20, 2023 Completion: Feb 5, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study enrollment was halted due to pandemic-related slow accrual

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

Other Lung Cancer trials with similar outcome

Browse all Lung Cancer trials

Listed as NCT04364048, this PHASE2 trial focuses on Lung Cancer and Non-small Cell Carcinoma and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 14 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~May 2024 · 10 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – present · 18 months · monthly snapshot

Change History

14 versions recorded

  1. Jan 2025 — Present [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 9 earlier versions

  1. Jun 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  4. Feb 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  5. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  6. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  8. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. May 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Providence Cancer Center, Earle A. Chiles Research Institute
  • Rachel Sanborn
Data source: Hoosier Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations